Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMA panel grants positive opinion on ODD of Inventiva’s IVA337
SSc or scleroderma is a connective tissue disease of autoimmune origin with severe physical and psychosocial consequences. IVA337 is a patent protected new chemical entity (NCE) that has
SSc or scleroderma is a connective tissue disease of autoimmune origin with severe physical and psychosocial consequences. IVA337 is a patent protected new chemical entity (NCE) that has
As part of the deal, Abide and Oxford will study the role of monoacylglycerol lipase (MGLL) inhibitors in altering endocannabinoid tone in the human brain. The partnership will
The trial is designed to evaluate the efficacy and safety of gevokizumab in treating the active ulcers caused by this disease. In February 2014, the US Food and
Currently, participants are being sought for a new phase of a trial designed to measure the prevalence of addiction to OTC medicines. The University’s PhD student in Academic
Imbruvica is co-developed by Pharmacyclics and Janssen and commercialized outside the US by Janssen affiliates. Janssen affiliates market Imbruvica in Europe, Middle East and Africa as well as
As part of the deal, Waterstone has an option to license two additional cyclophilin inhibitors from Scynexis. In return, Scynexis will receive an upfront payment and is eligible
An active moiety of the prodrug isavuconazonium, Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal being developed to treat severe invasive and life-threatening fungal infections. The
The drug is indicated for the long-term, once-daily, add-on maintenance treatment of asthma in patients 12 years of age and older who remain symptomatic on at least inhaled
Under the new $4.8m strategic alliance, ex scientia received an upfront payment of $1m. As part of the deal, Sunovion will receive exclusive worldwide rights to the resulting
Galecto’s TD139 is currently in Phase I development and is designed to treat idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions. TD139 is a highly potent, specific